Pleiotropic effects of hymecromone in the treatment of chronic liver and biliary tract diseases

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Liver fibrosis is a common end result of chronic hepatocyte damage. Clinical progress in the development of anti-fibrosis drugs is gaining momentum: various pharmaceutical products, including hymecromone (4-MU) are belonging to that group.

The aim: to evaluate the anti-inflammatory and antifibrotic efficacy of hymecromone in patients with combined biliary and hepatic pathology.

Material and methods. 55 patients (31 females and 24 males) aged 18–75 years with chronic hepatitis of various etiologies and liver fibrosis (F 1–4) associated with biliary pathology were involved in the study. Twenty of them completed the study. All participants were prescribed hymecromone 200 mg three times daily for 3 weeks, followed by a 1-week break; the course was repeated for 6 months. All patients also received ursodeoxycholic acid at a dose of 10 mg/kg body weight at night continuously for 6 months.

Results. All patients reported improved well-being, increased physical activity, and increased work capacity during the treatment period. They also experienced a statistically significant decrease in biochemical markers (p = 0.001–0.049) and positive statistically significant changes in fibroelastometry parameters (p < 0.001) after 6 months of observation.

Conclusion. Our treatment regimen demonstrated significant antifibrotic efficacy (p = 0.001) and was accompanied by a statistically significant reduction in liver markers. It is necessary to continue the further studies on the use of hymecromone (4-MU) in chronic liver diseases.

About the authors

Ekaterina Y. Plotnikova

Kemerovo State Medical University

Author for correspondence.
Email: eka-pl@rambler.ru
ORCID iD: 0000-0002-6150-1808

MD, Dr. Sci. (Medicine), professor, professor of the Department of postgraduate education and nursing, head of the clinical gastroenterology course

Russian Federation, Kemerovo

Lyudmila G. Vologzhanina

Academician E.A. Wagner Perm State Medical University; GASTROTSENTER LLC

Email: ludovica@mail.ru
ORCID iD: 0000-0003-3105-4645

MD, PhD (Medicine), associate professor of the Department of faculty therapy No. 1

Russian Federation, Perm; Perm

Sofia R. Druzhinina

GASTROTSENTER LLC

Email: eka-pl@rambler.ru

MD, gastroenterologist

Russian Federation, Perm

Maxim A. Sinkov

Research Institute for Complex Issues of Cardiovascular Diseases

Email: fox2you@mail.ru
ORCID iD: 0000-0002-2494-8694
SPIN-code: 8327-3979

MD, PhD (Medicine), cardiovascular surgeon

Russian Federation, Kemerovo

Yuri V. Kotelevtsev

Center for Biomedical Technologies, Skolkovo Institute of Science and Technology (Skoltech)

Email: y.kotelevtsev@skoltech.ru
ORCID iD: 0000-0002-7255-7794

Dr. Sci. (Biology), professor, Center for Biomedical Technologies

Russian Federation, Moscow

References

  1. Lambrecht J, van Grunsven LA, Tacke F. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opin Pharmacother. 2020;21(13):1637–50. PMID: 32543284. https://doi.org/10.1080/14656566.2020.1774553
  2. Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4):875. PMID: 32260126. PMCID: PMC7226751. https://doi.org/10.3390/cells9040875
  3. Zhao J, Qi YF, Yu YR. STAT3: A key regulator in liver fibrosis. Ann Hepatol. 2021;21:100224. PMID: 32702499. https://doi.org/10.1016/j.aohep.2020.06.010
  4. Chen S, Wu Z, Zhang J, Lin Y, Xie J, Yin D, Zhu Y. Research and application of medicines for treating liver fibrosis: Current status and prospects. Front Pharmacol. 2025;16:1582258. PMID: 40703362. PMCID: PMC12283635. https://doi.org/10.3389/fphar.2025.1582258
  5. Jeon S, Carr R. Alcohol effects on hepatic lipid metabolism. J Lipid Res. 2020;61(4):470–79. PMID: 32029510. PMCID: PMC7112138. https://doi.org/10.1194/jlr.R119000547
  6. Odenwald MA, Paul S. Viral hepatitis: Past, present, and future. World J Gastroenterol. 2022;28(14):1405–29. PMID: 35582678. PMCID: PMC9048475. https://doi.org/10.3748/wjg.v28.i14.1405
  7. Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W et al. Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63. PMID: 35287643. PMCID: PMC8919523. https://doi.org/10.1186/s12902-022-00980-1
  8. Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: Diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol. 2015;13(12):2062–70. PMID: 26226097. https://doi.org/10.1016/j.cgh.2015.07.029
  9. Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet Neurol. 2015;14(1):103–13. PMID: 25496901. PMCID: PMC4336199. https://doi.org/10.1016/S1474-4422(14)70190-5
  10. Kane SF, Roberts C, Paulus R. Hereditary hemochromatosis: Rapid evidence review. Am Fam Physician. 2021;104(3):263–70. PMID: 34523883.
  11. Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol. 2014;60(1):210–23. PMID: 24084655. https://doi.org/10.1016/j.jhep.2013.09.020
  12. Sanyal AJ, Castera L, Wong VW. Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2023;21(8):2026–39. PMID: 37062495. https://doi.org/10.1016/j.cgh.2023.03.042
  13. Kaplan DE, Teerlink CC, Schwantes-An TH, Norden-Krichmar TM, DuVall SL, Morgan TR et al. Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction-associated steatotic liver disease. Hepatol Commun. 2024;8(7):e0487. PMID: 38967582. PMCID: PMC11227360. https://doi.org/10.1097/HC9.0000000000000487
  14. Ericson E, Bergenholm L, Andreasson AC, Dix CI, Knochel J, Hansson SF et al. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans. Hepatol Commun. 2022;6(10):2689–701. PMID: 35833455. PMCID: PMC9512469. https://doi.org/10.1002/hep4.2032
  15. Liu J, Ginsberg HN, Reyes-Soffer G. Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism. Curr Opin Lipidol. 2024;35(3):157–61. PMID: 38465912. PMCID: PMC11168781. https://doi.org/10.1097/MOL.0000000000000930
  16. Fabbrini E, Rady B, Koshkina A, Jeon JY, Ayyar VS, Gargano C et al. Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD. N Engl J Med. 2024;391(5):475–76. PMID: 39083780. https://doi.org/10.1056/NEJMc2402341
  17. Moran-Salvador E, Mann J. Epigenetics and liver fibrosis. Cell Mol Gastroenterol Hepatol. 2017;4(1):125–34. PMID: 28593184. PMCID: PMC5453904. https://doi.org/10.1016/j.jcmgh.2017.04.007
  18. Barchetta I, Zampieri M, Cimini FA, Dule S, Sentinelli F, Passarella G et al. Association between active DNA demethylation and liver fibrosis in individuals with metabolic-associated steatotic liver disease (MASLD). Int J Mol Sci. 2025;26(3):1271. PMID: 39941038. PMCID: PMC11818491. https://doi.org/10.3390/ijms26031271
  19. Akkız H, Gieseler RK, Canbay A. Liver fibrosis: From basic science towards clinical progress, focusing on the central role of hepatic stellate cells. Int J Mol Sci. 2024;25(14):7873. PMID: 39063116. PMCID: PMC11277292. https://doi.org/10.3390/ijms25147873
  20. Liu Y, Wen D, Ho C, Yu L, Zheng D, O’Reilly S et al. Epigenetics as a versatile regulator of fibrosis. J Transl Med. 2023;21(1):164. PMID: 36864460. PMCID: PMC9983257. https://doi.org/10.1186/s12967-023-04018-5
  21. Li H, Liu T, Yang Y, Cho WC, Flynn RJ, Harandi MF et al. Interplays of liver fibrosis-associated microRNAs: Molecular mechanisms and implications in diagnosis and therapy. Genes Dis. 2022;10(4):1457–69. PMID: 37397560. PMCID: PMC10311052. https://doi.org/10.1016/j.gendis.2022.08.013
  22. Rodimova S, Mikhailova L, Arabuli K, Kozlov D, Kozlova V, Kuzmin D et al. MicroRNA-200a as a therapeutic agent for acute and chronic liver pathologies and regeneration. Biomaterials. 2026;331:124125. PMID: 41855855. https://doi.org/10.1016/j.biomaterials.2026.124125
  23. Schwabe RF, Luedde T. Apoptosis and necroptosis in the liver: a matter of life and death. Nat Rev Gastroenterol Hepatol. 2018;15(12):738–52. PMID: 30250076. PMCID: PMC6490680. https://doi.org/10.1038/s41575-018-0065-y
  24. Woolbright BL, Jaeschke H. Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure. J Hepatol. 2017;66(4):836–48. PMID: 27913221. PMCID: PMC5362341. https://doi.org/10.1016/j.jhep.2016.11.017
  25. Chen M, Zhong W, Xu W. Alcohol and the mechanisms of liver disease. J Gastroenterol Hepatol. 2023;38(8):1233–40. PMID: 37423758. https://doi.org/10.1111/jgh.16282
  26. Banerjee A, Farci P. Fibrosis and hepatocarcinogenesis: Role of gene-environment interactions in liver disease progression. Int J Mol Sci. 2024;25(16):8641. PMID: 39201329. PMCID: PMC11354981. https://doi.org/10.3390/ijms25168641
  27. Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(39):14205–18. PMID: 25339807. PMCID: PMC4202349. https://doi.org/10.3748/wjg.v20.i39.14205
  28. Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: A comprehensive review. Cardiovasc Diabetol. 2024;23(1):346. PMID: 39342178. PMCID: PMC11439309. https://doi.org/10.1186/s12933-024-02434-5
  29. Zhao YQ, Deng XW, Xu GQ, Lin J, Lu HZ, Chen J. Mechanical homeostasis imbalance in hepatic stellate cells activation and hepatic fibrosis. Front Mol Biosci. 2023;10:1183808. PMID: 37152902. PMCID: PMC10157180. https://doi.org/10.3389/fmolb.2023.1183808
  30. Yang AT, Kim YO, Yan XZ, Abe H, Aslam M, Park KS et al. Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis. Cell Mol Gastroenterol Hepatol. 2023;15(4):841–67. PMID: 36521660. PMCID: PMC9972574. https://doi.org/10.1016/j.jcmgh.2022.12.005
  31. Liu X, Liu D, Tan C, Feng W. Gut microbiome-based machine learning for diagnostic prediction of liver fibrosis and cirrhosis: A systematic review and meta-analysis. BMC Med Inform Decis Mak. 2023;23(1):294. PMID: 38115019. PMCID: PMC10731850. https://doi.org/10.1186/s12911-023-02402-1
  32. Fuchs CD, Simbrunner B, Baumgartner M, Campbell C, Reiberger T, Trauner M. Bile acid metabolism and signalling in liver disease. J Hepatol. 2025;82(1):134–53. PMID: 39349254. https://doi.org/10.1016/j.jhep.2024.09.032
  33. Tang YL, Zhu L, Tao Y, Lu W, Cheng H. Role of targeting TLR4 signaling axis in liver-related diseases. Pathol Res Pract. 2023;244:154410. PMID: 36917917. https://doi.org/10.1016/j.prp.2023.154410
  34. Wang XX, Xie C, Libby AE, Ranjit S, Levi J, Myakala K et al. The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice. J Biol Chem. 2022;298(11):102530. PMID: 36209823. PMCID: PMC9638804. https://doi.org/10.1016/j.jbc.2022.102530
  35. Hizo GH, Rampelotto PH. The impact of probiotic Bifidobacterium on liver diseases and the microbiota. Life (Basel). 2024;14(2):239. PMID: 38398748. PMCID: PMC10890151. https://doi.org/10.3390/life14020239
  36. Gleeson J, Barry J, O’Reilly S. Use of liver imaging and biopsy in clinical practice. N Engl J Med. 2017;377(23):2296. PMID: 29215220. https://doi.org/10.1056/NEJMc1712445
  37. Wendum D, Lacombe K, Chevallier M, Callard P, Valet F, Miailhes P et al. Histological scoring of fibrosis and activity in HIV-chronic hepatitis B related liver disease: Performance of the METAVIR score assessed on virtual slides. J Clin Pathol. 2009;62(4):361–63. PMID: 19126564. https://doi.org/10.1136/jcp.2008.062349
  38. Scott DR, Levy MT. Liver transient elastography (Fibroscan): A place in the management algorithms of chronic viral hepatitis. Antivir Ther. 2010;15(1):1–11. PMID: 20167986. https://doi.org/10.3851/IMP1474
  39. Xu X, Jin J, Liu Y. Performance of FibroScan in grading steatosis and fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Arab J Gastroenterol. 2023;24(4):189–97. PMID: 37996351. https://doi.org/10.1016/j.ajg.2023.08.003
  40. Liguori A, Esposto G, Ainora ME, Mignini I, Borriello R, Galasso L et al. Liver elastography for liver fibrosis stratification: A Comparison of three techniques in a biopsy-controlled MASLD Cohort. Biomedicines. 2025;13(1):138. PMID: 39857722. PMCID: PMC11762890. https://doi.org/10.3390/biomedicines13010138
  41. Xiao H, Shi M, Xie Y, Chi X. Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis. PLoS One. 2017;12(11):e0186660. PMID: 29107943. PMCID: PMC5673175. https://doi.org/10.1371/journal.pone.0186660
  42. Castera L, Rinella ME, Tsochatzis EA. Noninvasive assessment of liver fibrosis. N Engl J Med. 2025;393(17):1715–29. PMID: 41160822. https://doi.org/10.1056/NEJMra2403308
  43. Honda Y, Yoneda M, Kobayashi T, Iwaki M, Kawamura N, Nogami A et al. Meta-analysis of the diagnostic accuracy of serum type IV collagen 7S concentration for the staging of liver fibrosis in nonalcoholic fatty liver disease. Hepatol Res. 2023;53(3):219–27. PMID: 36378589. https://doi.org/10.1111/hepr.13857
  44. Li W, Chi Y, Xiao X, Li J, Sun M, Sun S et al. Plasma FSTL-1 as a noninvasive diagnostic biomarker for patients with advanced liver fibrosis. Hepatology. 2025;82(3):669–82. PMID: 40833998. PMCID: PMC12356556. https://doi.org/10.1097/HEP.0000000000001167
  45. Cerrito L, Galasso L, Iaccarino J, Pizzi A, Termite F, Esposto G et al. Present and future perspectives in the treatment of liver fibrosis. Pharmaceuticals (Basel). 2025;18(9):1321. PMID: 41011192. PMCID: PMC12472440. https://doi.org/10.3390/ph18091321
  46. Qu J, Qin W, Dong M, Ma Z, Li S, Liu R et al. Liver fibrosis: Molecular pathogenesis and therapeutic interventions. MedComm. 2026;7(5):e70750. PMID: 42087905. PMCID: PMC13136092. https://doi.org/10.1002/mco2.70750
  47. Wang X, Wang L, Geng L, Tanaka N, Ye B. Resmetirom ameliorates NASH-model mice by suppressing STAT3 and NF-κB signaling pathways in an RGS5-dependent manner. Int J Mol Sci. 2023;24(6):5843. PMID: 36982915. PMCID: PMC10058113. https://doi.org/10.3390/ijms24065843
  48. Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G et al.; for the ATLAS Investigators. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology. 2021;73(2):625–43. PMID: 33169409. https://doi.org/10.1002/hep.31622
  49. Gao YS, Qian MY, Wei QQ, Duan XB, Wang SL, Hu HY et al. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice. Acta Pharmacol Sin. 2020;41(3):336–47. PMID: 31645659. PMCID: PMC7468331. https://doi.org/10.1038/s41401-019-0310-0
  50. Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, Ostergaard L, Vanni D et al. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: Baseline characteristics and design of the phase 3 ESSENCE trial. Aliment Pharmacol Ther. 2024;60(11–12):1525–33. PMID: 39412509. PMCID: PMC11599791. https://doi.org/10.1111/apt.18331
  51. Desjardins EM, Wu J, Lavoie DCT, Ahmadi E, Townsend LK, Morrow MR et al. Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice. Cell Rep Med. 202;4(9):101193. PMID: 37729871. PMCID: PMC10518624. https://doi.org/10.1016/j.xcrm.2023.101193
  52. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications. Lancet. 2021;398(10296):262–76. PMID: 34216571. https://doi.org/10.1016/S0140-6736(21)00536-5
  53. Nguyen G, Park SY, Le CT, Park WS, Choi DH, Cho EH. Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition. Biochem Biophys Res Commun. 2018;495(4):2649–56. PMID: 29278707. https://doi.org/10.1016/j.bbrc.2017.12.143
  54. Puengel T, Tacke F. Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2023;32(6):451–61. PMID: 37376813. https://doi.org/10.1080/13543784.2023.2230115
  55. Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med. 2023;389(11):998–1008. PMID: 37356033. PMCID: PMC10718287. https://doi.org/10.1056/NEJMoa2304286
  56. Ye HL, Zhang JW, Chen XZ, Wu PB, Chen L, Zhang G. Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy. Life Sci. 2020;242:117175. PMID: 31843528. https://doi.org/10.1016/j.lfs.2019.117175
  57. Sanyal AJ, Ratziu V, Loomba R, Anstee QM, Kowdley KV, Rinella ME et al. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. J Hepatol. 2023;79(5):1110–20. PMID: 37517454. https://doi.org/10.1016/j.jhep.2023.07.014
  58. Loomba R, Bedossa P, Grimmer K, Kemble G, Bruno Martins E, McCulloch W et al. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2024;9(12):1090–100. PMID: 39396529. https://doi.org/10.1016/S2468-1253(24)00246-2
  59. Okanoue T, Sakamoto M, Harada K, Inagaki M, Totsuka N, Hashimoto G, Kumada H. Efficacy and safety of apararenone (MT-3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study. Hepatol Res. 2021;51(9):943–56. PMID: 34260795. https://doi.org/10.1111/hepr.13695
  60. Fraser DA, Wang X, Lund J, Nikolic N, Iruarrizaga-Lejarreta M, Skjaeret T et al. A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. J Hepatol. 2022;76(4):800–11. PMID: 34915054. https://doi.org/10.1016/j.jhep.2021.12.004
  61. Scorletti E, Creasy KT, Vujkovic M, Vell M, Zandvakili I, Rader DJ et al. Dietary vitamin E intake is associated with a reduced risk of developing digestive diseases and nonalcoholic fatty liver disease. Am J Gastroenterol. 2022;117(6):927–30. PMID: 35288522. PMCID: PMC9177739. https://doi.org/10.14309/ajg.0000000000001726
  62. Choi J, Nguyen VH, Przybyszewski E, Song J, Carroll A, Michta M et al. Statin use and risk of hepatocellular carcinoma and liver fibrosis in chronic liver disease. JAMA Intern Med. 2025;185(5):522–30. PMID: 40094696. PMCID: PMC11915111. https://doi.org/10.1001/jamainternmed.2025.0115
  63. Navarro VJ, Belle SH, D’Amato M, Afdhal N, Brunt EM, Fried MW et al.; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. PLoS ONE 2019;14(10):e0223915. PMID: 31600349. PMCID: PMC6786547. https://doi.org/10.1371/journal.pone.0223915
  64. Ramachandran G, Pottakkat B. Probiotics – a promising novel therapeutic approach in the management of chronic liver diseases. J Med Food. 2024;27(6):467–76. PMID: 38574254. https://doi.org/10.1089/jmf.2023.K.0129
  65. Israelsen M, Madsen BS, Torp N, Johansen S, Hansen CD, Detlefsen S et al.; GALAXY; MicrobLiver Consortia. Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):523–32. PMID: 36893774. PMCID: PMC10172147. https://doi.org/10.1016/S2468-1253(23)00010-9
  66. Ng SC, Xu Z, Mak JWY, Yang K, Liu Q, Zuo T et al. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: A 24-week, double-blind, randomised controlled trial. Gut. 2022;71(4):716–23. PMID: 33785557. https://doi.org/10.1136/gutjnl-2020-323617
  67. Tsitrina AA, Halimani N, Andreichenko IN, Sabirov M, Nesterchuk M, Dashenkova NO et al. 4-methylumbelliferone targets revealed by public data analysis and liver transcriptome sequencing. Int J Mol Sci. 2023;24(3):2129. PMID: 36768453. PMCID: PMC9917189. https://doi.org/10.3390/ijms24032129
  68. Плотникова Е.Ю., Вологжанина Л.Г., Азанов А., Сухих А.С. Коморбидность заболеваний печени и билиарного тракта. Фарматека. 2025;32(1):76–86. [Plotnikova EYu, Vologzhanina LG, Azanov AZ, Sukhikh AS. Comorbidity of liver and biliary tract diseases. Farmateka. 2025;32(1):76–86 (In Russ.)]. EDN: SBEDSW. https://doi.org/10.18565/pharmateca.2025.1.76-86
  69. Плотникова Е.Ю. Известный и неизвестный гимекромон. Consilium Medicum. 2024;26(5):324–330. [Plotnikova EYu. Known and unknown hymecromone. A review. Consilium Medicum. 2024;26(5):324–330 (In Russ.)]. EDN: OPOFNF. https://doi.org/10.26442/20751753.2024.5.202877
  70. Охлобыстин А.В., Шульпекова Ю.О., Зольникова О.Ю., Ивашкин В.Т. Роль гимекромона в лечении дисфункции билиарного тракта: систематический обзор и метаанализ клинических исследований. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2026;36(2):46–58. [Okhlobystin AV, Shulpekova YuO, Zolnikova OYu, Ivashkin VT. The role of hymecromone in the treatment of biliary tract dysfunction: A systematic review and meta-analysis of clinical trials. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2026;36(2):46–58 (In Russ.)]. EDN: NHKKDNю https://doi.org/10.22416/1382-4376-2026-1995-5633
  71. Плотникова Е.Ю., Вологжанина Л.Г., Азанов А., Сухих А.С. Коморбидность заболеваний печени и билиарного тракта. Фарматека. 2025;32(1):76–86. [Plotnikova EYu, Vologzhanina LG, Azanov AZ, Sukhikh AS. Comorbidity of liver and biliary tract diseases. Farmateka. 2025;32(1):76–86 (In Russ.)]. EDN: SBEDSW. https://doi.org/10.18565/pharmateca.2025.1.76-86
  72. Kim SM, Song GY, Shim A, Lee JH, Eom CB, Liu C et al. Hyaluronan synthase 2, a target of miR-200c, promotes carbon tetrachloride-induced acute and chronic liver inflammation via regulation of CCL3 and CCL4. Exp Mol Med. 2022;54(6):739–52. PMID: 35662287. PMCID: PMC9256637. https://doi.org/10.1038/s12276-022-00781-5
  73. Andreichenko IN, Tsitrina AA, Fokin AV, Gabdulkhakova AI, Maltsev DI, Perelman GS et al. 4-methylumbelliferone prevents liver fibrosis by affecting hyaluronan deposition, FSTL1 expression and cell localization. Int J Mol Sci. 2019;20(24):6301. PMID: 31847129. PMCID: PMC6941058. https://doi.org/10.3390/ijms20246301
  74. Kultti A, Pasonen-Seppänen S, Jauhiainen M, Rilla KJ, Karna R, Pyoria E et al. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res. 2009;315(11):1914–23. PMID: 19285976. https://doi.org/10.1016/j.yexcr.2009.03.002
  75. Rosser JI, Nagy N, Goel R, Kaber G, Demirdjian S, Saxena J et al. Oral hymecromone decreases hyaluronan in human study participants. J Clin Invest. 2022;132(9):e157983. PMID: 35499083. PMCID: PMC9057598. https://doi.org/10.1172/JCI157983
  76. Nagy N, Gurevich I, Kuipers HF, Ruppert SM, Marshall PL, Xie BJ et al. 4-Methylumbelliferyl glucuronide contributes to hyaluronan synthesis inhibition. J Biol Chem. 2019;294(19):7864–77. PMID: 30914479. PMCID: PMC6514619. https://doi.org/10.1074/jbc.RA118.006166

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 “Bionika Media” LLC

License URL: https://journals.eco-vector.com/2412-4036/about/editorialPolicies